Stocks Health care ACIU
NASDAQ · Health careAC Immune SA (ACIU)
AC Immune SA reported revenue of CHF 3.6M in fiscal 2025, down 86.9% from a year earlier. It posted a net loss of CHF 70.4M. In fiscal 2025 capital spending exceeded operating cash flow by CHF 70.2M. At December 31, 2025 it held CHF 26.8M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 13, 2026.
Key facts about AC Immune SA
- Net worth
- AC Immune SA has a market value (market cap) of $248.3M at the latest share price, and shareholders' equity of CHF 44.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was CHF 3.6M (-86.9% year on year), with a net loss of CHF 70.4M.
- Cash flow
- In fiscal 2025 operations used CHF 69.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 13, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What AC Immune SA does
AC Immune SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACIU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | CHF 3.6M | -CHF 70.4M | -CHF 0.70 | -CHF 70.2M |
| 2024 | CHF 27.3M | -CHF 50.9M | -CHF 0.51 | CHF 65.3M |
| 2023 | CHF 14.8M | -CHF 54.2M | -CHF 0.64 | -CHF 61.2M |
| 2022 | CHF 3.9M | -CHF 70.8M | -CHF 0.85 | -CHF 74.8M |
| 2021 | CHF 0 | -CHF 73M | -CHF 0.97 | -CHF 68.3M |
| 2020 | CHF 15.4M | -CHF 61.9M | -CHF 0.86 | -CHF 61.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What AC Immune SA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- October 2, 2026
- September 23, 2026
- September 3, 2026
- August 20, 2026
- August 11, 2026
- August 5, 2026
- June 30, 2026
- June 11, 2026
- June 11, 2026
Insider trades
What the people running AC Immune SA did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 11, 2026 | June Carl HowardDirector | Received as pay | 16,568 | - |
| June 11, 2026 | Buetler MonikaDirector | Received as pay | 17,751 | - |
| June 11, 2026 | Zuegel MartinInterim CEO, Director | Received as pay | 33,136 | - |
| June 11, 2026 | Aguiar-Lucander ReneeDirector | Received as pay | 16,568 | - |
| June 11, 2026 | Twyman Roy ErvinDirector | Received as pay | 16,568 | - |
| May 15, 2026 | Pfeifer AndreaChief Executive Officer, Director | Soldpre-planned (10b5-1) | 10,000 | $27.9K |
| April 15, 2026 | Pfeifer AndreaChief Executive Officer, Director | Bought | 10,000 | $31.4K |
| April 15, 2026 | Pfeifer AndreaChief Executive Officer, Director | Soldpre-planned (10b5-1) | 10,000 | $31.4K |
Who owns ACIU
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Affiris AG in Liqu13G, passive | 6.5% | December 13, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 43 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bvf Inc | 19,822,436 | 0 |
| Wells Fargo & Company | 1,004,041 | -243 |
| Renaissance Technologies LLC | 840,127 | +215,760 |
| Millennium Management LLC | 773,594 | -19,063 |
| BlackRock, Inc. | 519,274 | -5,004 |
| Dimensional Fund Advisors LP | 340,082 | -50,083 |
| Arrowstreet Capital, Limited Partnership | 232,953 | -172,705 |
| Citadel Advisors LLC | 207,606 | -59,627 |
| Morgan Stanley | 131,815 | +42,562 |
| Two Sigma Investments, LP | 102,825 | +63,734 |
| Qube Research & Technologies Ltd | 92,351 | new |
| UBS Group AG | 85,614 | -16,015 |
| Geode Capital Management, LLC | 61,854 | -1,747 |
| Susquehanna International Group, Llp | 53,369 | -35,893 |
| Jump Financial, LLC | 24,064 | +12,939 |
| Jane Street Group, LLC | 19,475 | -38,221 |
| Verdad Advisers, LP | 16,300 | new |
| China Universal Asset Management Co., Ltd. | 16,197 | -1,655 |
| Goldman Sachs Group Inc | 14,497 | -7,135 |
| Quadrature Capital Ltd | 12,991 | new |
Insiders
6 insiders reported holding 8,004,888 shares in total, about $19.5M at the last price.
| Holder | Shares |
|---|---|
| Pfeifer AndreaChief Executive Officer, Director | 7,650,576 |
| Twyman Roy ErvinDirector | 92,556 |
| Buetler MonikaDirector | 71,656 |
| Zuegel MartinInterim CEO, Director | 71,408 |
| June Carl HowardDirector | 67,556 |
| Aguiar-Lucander ReneeDirector | 51,136 |
Questions about ACIU
What does AC Immune SA do?
AC Immune SA is a company in the Health care sector, listed on NASDAQ as ACIU. Its shares trade on NASDAQ under the ticker ACIU.
What is AC Immune SA's net worth?
AC Immune SA has a market value (market cap) of $248.3M at the latest share price, and shareholders' equity of CHF 44.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AC Immune SA profitable?
No. In fiscal 2025 it reported a net loss of CHF 70.4M on revenue of CHF 3.6M.
How much revenue does AC Immune SA make?
In fiscal 2025 AC Immune SA reported revenue of CHF 3.6M. That is 86.9% less than a year earlier.
When did AC Immune SA last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 13, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 4, 2026.
Similar companies
Compare ACIU with
Follow ACIU
Get an email when AC Immune SA files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AC Immune SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.